...
首页> 外文期刊>Journal of Pain Research >Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data
【24h】

Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data

机译:在德国护理家庭居民中的痛苦和甘蓝丁醇的使用 - 基于法定健康保险数据的分析结果

获取原文

摘要

Background: Gabapentinoids (gabapentin and pregabalin) are psychoactive medications that are increasingly used for different conditions. Since there is evidence that psychotropic drugs, in general, are often inappropriately prescribed in elderly patients, we aimed to determine frequency and indications of gabapentinoid prescribing for nursing home residents. Methods: We analyzed data from a large German statutory health insurance database. Included were records from people ≥65 years-of-age, who were admitted to a nursing home between January 2010 and December 2014. We determined the number and proportion of common indications for on- and off-label prescriptions, the most frequent co-medications, and the characteristics of patients and prescribers. Results: Of 127,277 residents, 9539 (7.5%) received gabapentinoids and 4852 initiated treatment (4.0%; with 66.3% pregabalin). Median age of gabapentinoid initiators was 84 years (78.5% females). In these users, on-label prescribing was found in 57.4%, predominantly for neuropathic pain. Other painful conditions were also chief causes (84.7%) for off-label prescribing. Gabapentinoids were mainly started by general practitioners (64.5%) while pain specialists contributed 2%. Forty-six percent of users received additional opioids and in 27.5% gabapentinoids were prescribed only once. Conclusion: Gabapentinoids were frequently used in nursing home residents. Regular co-prescribing with opioids and psychotropic drugs might indicate employment to improve pain or assist treatment of conditions that are frequently associated with disruptive behavior such as dementia. However, more research is needed to better understand decision-making regarding gabapentinoid prescribing, especially in view of aggressive marketing, uncertain analgesic effects, problematic side effects, and uncritical use in the elderly.
机译:背景:加巴蛋白素(Gabapentin和Prafabalin)是越来越多地用于不同条件的精神活性药物。由于有证据表明,一般而言,一般而言之,在老年患者中往往是不恰当的处方,我们旨在确定养老院居民的甘蓝蛋白素的频率和适应症。方法:我们分析了大型德国法定健康保险数据库的数据。包括≥65岁的人的记录,他于2010年1月至2014年12月录取了一名疗养院。我们确定了符合标签处置处方的常见迹象的数量和比例,最常见的共同药物和患者和处方的特征。结果:127,277名居民,9539(7.5%)接受加巴蛋白蛋白质糖,4852种引发治疗(4.0%;普瑞巴林66.3%)。甘蓝产蛋白质引发剂的中位年龄为84岁(女性78.5%)。在这些用户中,在57.4%的情况下,标签的处方,主要用于神经性疼痛。其他痛苦的条件也是突破标准的主要原因(84.7%)。加巴蛋白原毒素主要由一般从业者(64.5%)开始,而痛苦专家贡献<2%。 46,60%的用户接受了额外的阿片类药物,在27.5%的加巴蛋白蛋白质中仅进行一次。结论:甘蓝产脂蛋白经常用于护理家庭居民。与阿片类药物和精神药物的常规共同调节可能表明就业,以改善与痴呆症等破坏性行为常相关的病症的疼痛或辅助治疗。然而,需要更多的研究来更好地了解关于甘蓝蛋白样原规定的决策,特别是考虑到攻击性营销,不确定的镇痛作用,有问题的副作用和在老年人的不共同用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号